Espicom publishes over 135 reports on companies developing anti-cancer drugs from the largest blue-chip multinational to smaller specialist organisations - and all phases of development from research to launched products.

For each company you can evaluate:
* Summary: At a glance review of agreements, products and R&D pipeline.
* Overview: Background, ownership structure and research techniques they have developed for drug discovery.
* Agreements: Key details of who the company is collaborating with, and on what.
* Product Portfolio: Product monographs, mechanism of action and indications approved and in development.
* R&D Pipeline: Concise summaries of products in research covering status, indication and clinical trials.
* Financials: An analysis of financial performance including P&L, R&D expenditure and funding. Incorporated in 1981, Aphton is a biopharmaceutical company focused on the development and commercialisation of pharmaceutical products for the treatment of cancer and gastrointestinal (GI) disease. Its research and development efforts are based on its proprietary active immunisation and monoclonal antibody (MAb) technologies. These technologies are based on key discoveries made by Aphton as well as its deep understanding of the central role of gastrin, a naturally-occurring hormone, and gastrin receptors. It is well documented in scientific literature that gastrin and gastrin receptors are critical to the onset, development, growth and spread of adenocarcinomas of the GI system, including those found in the stomach, pancreas, oesophagus, liver and throughout the colon and rectum.

Aphton is engaged in the research and development and clinical trials of its products, both independently and through various strategic alliances. It has financed its operations primarily through the sale of its equity securities.

Aphton's approach to the treatment of major diseases is to employ (anti) hormone therapy. Aphton's hormone therapy involves blocking certain hormones that play a critical role in these diseases. This is accomplished by immunising the patients with an immunogen that induces in them a directed Ab response which neutralises, and removes from circulation, the targeted hormone.